Our hepatocyte-specific Mettl3 knockin model and the whole-body Mettl3+/− knockout model suggest that METTL3 promotes NAFLD-HCC, particularly at the tumor stage. This evidence concerns the gene METTL3 and metabolic dysfunction-associated steatotic liver disease.